Altron Limited (JSE:AEL)

Sage Therapeutics Cash Flow Statement

Financials in millions ZAR. Fiscal year is March - February.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Net Income	390	-170	13	-104	12,154
Depreciation & Amortization	540	540	540	379	489
Other Amortization	310	258	167	276	256
Stock-Based Compensation	33	26	25	61	27
Other Operating Activities	118	162	187	281	-11,481
Change in Accounts Receivable	88	358	3	332	-1,174
Change in Inventory	146	440	-347	-122	53
Change in Accounts Payable	-188	-301	571	-175	1,476
Change in Other Net Operating Assets	138	82	-33	-79	38
Operating Cash Flow	1,575	1,395	1,126	849	1,838
Operating Cash Flow Growth	12.90%	23.89%	32.63%	-53.81%	41.71%
Capital Expenditures	-562	-457	-355	-334	-387
Sale of Property, Plant & Equipment	9	16	10	21	34
Cash Acquisitions	-	-	-84	-235	-252
Divestitures	3	15	-2	138	735
Sale (Purchase) of Intangibles	-146	-110	-118	-62	-97
Other Investing Activities	2	3	-12	-38	-114
Investing Cash Flow	-694	-533	-561	-510	-81
Long-Term Debt Issued	425	1,275	850	300	-
Long-Term Debt Repaid	-656	-2,014	-1,207	-372	-1,634
Net Debt Issued (Repaid)	-231	-739	-357	-72	-1,634
Common Dividends Paid	-285	-170	-152	-442	-220
Other Financing Activities	-	-4	-	-	-84
Financing Cash Flow	-516	-913	-509	-514	-1,938
Foreign Exchange Rate Adjustments	-5	-6	11	-3	29
Miscellaneous Cash Flow Adjustments	6	-7	15	-27	-
Net Cash Flow	366	-64	82	-205	-152
Free Cash Flow	1,013	938	771	515	1,451
Free Cash Flow Growth	8.00%	21.66%	49.71%	-64.51%	64.51%
Free Cash Flow Margin	10.45%	9.68%	9.02%	6.44%	19.20%
Free Cash Flow Per Share	2.58	2.41	2.00	1.36	3.86
Cash Interest Paid	210	245	251	241	324
Cash Income Tax Paid	105	131	50	94	226
Levered Free Cash Flow	793.88	1,229	795.13	569.13	-455.63
Unlevered Free Cash Flow	904.5	1,347	916.38	682.25	-303.13
Change in Net Working Capital	-122	-684	-283	-112	796

Updated Nov 3, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.